Compounds for the treatment of canine Leishmaniosis

Patent number:

P202230181

No items found.

New family of compounds with demonstrated in vitro efficacy against intracellular parasites responsible for leishmaniasis and American trypanosomiasis or Chagas disease. Pharmacokinetic and toxicity studies have been conducted in rats, as well as preliminary efficacy studies in a murine model.

Countries:

Spain

Regions:

Community of Madrid

Centers:

CSIC

Other entities:

Sectors:

Food & Agro

Subsectors:

Pharmaceuticals

TRL Level:

TRL 4 – technology validated in lab

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

Applications

Los compuestos desarrollados han demostrado 100% de eficacia in vitro sobre parásitos causantes de leishmaniosis. El índice terapéutico (in vitro) hacía estos parásitos es alto (> 76 contra Leishmania, > 69 contra T. cruzi). Se han obtenido datos prometedores en ensayos de eficacia in vivo en modelo murino de Leishmaniosis visceral mediante administración oral del compuesto líder.

Comments

Other related patents

Aerospace

Automotive & Rail

Food & Agro

New & Sustainable Materials

Construction

PROCEDURE FOR IMPROVING THE PROPERTIES OF GYPSUM SHAPED PIECES

Countries

Spain

Food & Agro

RAIN WATER COLLECTION SYSTEM IN A RENEWABLE ENERGY PLANT FOR THE ENERGY OPTIMISATION OF THE PLANT

Countries

Spain

Food & Agro

PROCESS FOR THE AQUEOUS EXTRACTION OF BIOSURFACTANTS FROM CORN STEEP LIQUOR

Countries

Spain

Get back to patents directory